Background Most head and neck squamous-cell carcinomas (HNSCCs) are driven by p16
INK4A inactivation and cyclin D1 overexpression that results in hyperactivation of cyclin …

Objectives This study examined whether palbociclib and cetuximab prolonged overall
survival (OS) versus placebo and cetuximab. Materials and methods In this double-blind …

Objectives To test the safety of the CDK4/6 inhibitor palbociclib with cetuximab in patients
with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Materials and …

The loss of p16 is a signature event in Human Papilloma Virus (HPV)-negative head and
neck squamous cell carcinoma (HNSCC) that leads to increased Cyclin Dependent Kinase …

Purpose Human papillomavirus negative (HPV-ve) head and neck squamous cell
carcinoma (HNSCC) has a poor prognosis compared with HPV+ ve HNSCCs. Expression of …

Clinical decision making for human papillomavirus (HPV)-negative head and neck
squamous cell carcinoma (HNSCC) is predominantly guided by disease stage and anatomic …

Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer,
a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth …

Cancers of the head and neck that arise from habitual exposure to carcinogens have lower
cure rates than those that arise from infection with human papillomavirus (HPV), and …

Background Tumor human papillomavirus (HPV) status is an important prognostic factor in
locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) …

Abstract The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular
Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan …